MLL1

SeqLL’s Single-Molecule Nucleosome Imaging Method Published in Peer Reviewed Cell Reports Journal

Retrieved on: 
Monday, June 13, 2022
Molecule, Glioma, Company, Intellectual property, Research, Knowledge, Neoplasm, Weizmann Institute of Science, Form, Forward-looking statement, CEO, Nature, RNA, Security (finance), Disease, Brain, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, MLL1, Risk, Master of Science, GLOBE, Immunology, Technology, SQL, Cell Reports, NASDAQ, Department, Single molecule fluorescent sequencing, Nucleosome, Genomics, Cancer, Medical imaging, Fine chemical, Science, Doctor of Philosophy

The paper, entitled: H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape, applied SeqLL developed single-molecule imaging methods to look at cell mutations associated with pediatric brain cancers.

Key Points: 
  • The paper, entitled: H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape, applied SeqLL developed single-molecule imaging methods to look at cell mutations associated with pediatric brain cancers.
  • We were thrilled to see the Shema Lab apply this technology to deepen the understanding of cancer on the cellular level.
  • This research builds upon the 2016 Science publication Single-molecule decoding of combinatorially modified nucleosomes, led by the laboratory of Dr. Bradley Bernstein.
  • In sum, our experienced team works with our collaborators to develop innovative solutions tailored to the needs of each specific project.

BridGene Biosciences' IMTAC ™ Small Molecule Discovery Platform Featured in Multiple Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, October 7, 2021
SAR, TEAD, Sunitinib, SAN, Transforming protein RhoA, Drug discovery, Conference, Liposarcoma, TCGA, Cell, Nm, Protein, Glioblastoma, Diagnosis, Cancer, Immortalised cell line, NF2, Education, American Association for Cancer Research, Entrepreneurship, The Cancer Genome Atlas, Factor X, ELISA, WDR5, AACR, GTPase, Stomach, CDH1, Gene expression, CEO, Mesothelioma, MLL1, American Association, Association, IC50, Disease, Patient, Science, DGC, Research, Technology, Pharmaceutical industry, Vaccine, Fine chemical, Mobile phone

The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.

Key Points: 
  • The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.
  • "This is among the most prominent scientific gatherings addressing drug discovery and molecular targets.
  • Overall, our presentations describe our IMTAC platform technology and its capabilities, the discovery of novel small-molecule inhibitors for undruggable targets, and the identification of previously unknown targets for approved small-molecule drugs."
  • BridGene used the IMTAC platform to screen its unique covalent library against live-cell proteomes and discovered small-molecule ligands for WDR5.